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Background: The strut thickness and deliverability of BVS may increase procedural time, contrast volume and fluoroscopy time, especially in complex lesions. Methods: In this study, 205 consecutive patients treated with either BVS (n¼99) or drug eluting stent (DES) (n¼106) between May 2010 and May 2014 were enrolled. Results: The number of complex lesions (ACC/AHA lesion classification type B2 and C) between BVS and DES group (84.7% vs. 90.6%, p¼0.01) was similar. Pre and post-balloon dilatation were performed more frequently in the BVS group compared to the DES group (97.1% vs. 79.4%, p< 0.01; 99.2% vs. 79.4%, p< 0.01, respectively). Maximum post dilatation balloon size was larger and maximum inflation pressure was higher in the BVS compared to the DES group (3.2AE0.4 mm vs. 3.0AE0.1 mm, p¼0.01; 21.1AE5.1 atm vs. 19.2AE5.0 atm, p< 0.01, respectively), despite similar quantitative coronary angiogram (QCA) results. Procedure time, amount of contrast and fluoroscopy time in BVS group were increased significantly compared to those in the DES group (Table) . In multivariable analysis, after adjustment for SYNTAX score, chronic total occlusion and lesion length by QCA, BVS use was identified as an independent predictor of long procedure time (> 120 min.) (odds ratio: 4.9, 95% confidence interval: 2.67-9.36, p< 0.001).
Conclusions: Treating complex lesions with BVS requires longer procedure/ fluoroscopy times and larger volumes of contrast as compared to DES implantation to achieve similar procedural success rates and results. Improvements in scaffold design may reduce the need for meticulous lesion predilatation with dedicated devices and increase the spectrum of lesions amenable to treatment with BVS. Background: Everolimus-eluting bioresorbable vascular scaffolds (BVS) are increasingly used in patients with complex coronary anatomies. However, data on BVS in such indications are scarce. We thus sought to evaluate the safety and efficacy of ABSORB BVS in patients with complex coronary lesions. Methods: Consecutive patients (n¼150) undergoing BVS implantation at a tertiary care center entered a prospective registry. All patients underwent a detailed assessment of clinical and procedural data. Clinical follow-up was performed 7AE5 months following the index procedure and was completed in all patients. Major adverse cardiac events (MACE) included the occurrence of death, myocardial reinfarction, stent thrombosis and target lesion revascularization. Complex coronary artery disease was defined as type B2 or C lesions. Device success was defined as attainment of < 30% final residual stenosis. Procedural success was defined as device success without periprocedural complications. Clinical success was defined as procedural success and absence of MACE within follow-up. Results: Complex coronary lesions were present in 45.3% (n¼68) of patients. Baseline characteristics such as age, gender or left ventricular ejection fraction did not differ significantly between patients with type B2/C lesions versus those with type A/B1 lesions (all p>0.05). The number and length of BVS were higher in patients with complex lesions (1.4AE0.6 vs. 1.1AE0.3, p< 0.001 / 32AE13 vs. 19AE6mm, p< 0.001). Device success rate was high in both groups (97.1 vs. 97.6%, p¼1.00). At a relatively low rate of periprocedural complications (edge dissection n¼7, side branch occlusion n¼2) procedural success did not differ significantly in patients with complex lesions in comparison to patients with noncomplex lesions (91.2 vs. 95.1%, p¼0.51). The majority of patients remained free of angina within follow-up (85.3 vs. 92.7%, p¼0.19). MACE occurred in 1.5% (n¼1) of patients with type B2/C lesions versus 7.3% (n¼6) with type A/B1 lesions (p¼0.13). Finally, clinical success was comparable in both groups (89.7 vs. 87.9%, p¼0.80). Conclusions: BVS in complex coronary lesions appear to be promising in terms of safety and efficacy. Background: One of the hypothesized long-term clinical benefits of Absorb BVS is plaque regression (reduction in plaque volume) and stabilization (reduction in necrotic and lipid composition). This study evaluates the effect of Absorb BVS on plaque size and composition in a familial hypercholesterolemic (FH) swine model. We present here the IVUS results at 1-year follow-up. Methods: Ten-month-old female FH swine were fed an atherogenic diet for 21 weeks. One week into the feeding, coronary arteries were balloon injured. Twenty weeks post injury, intervened segments were imaged by IVUS for lesion progression and randomly implanted with either Absorb BVS or metallic drug-eluting stents (DES, XIENCEÔ V) at a 2:1 ratio. All animals were imaged by angiography, IVUS and OCT post implant and at an interim 1-year follow up. Results: Plaque area (PA), %PA (as percentage of EEL area) and plaque tissue composition were statistically similar for both device groups at pre and post implant (baseline) demonstrating a good randomization of the study. At 1-year follow-up, the implanted vessel (Absorb ¼ 23, DES ¼ 11) sizes remained unchanged. Change in the mean PA from baseline to 1 year was -0.22AE2.61mm2 for BVS and 1.15AE1.36mm2 for DES (p ¼ 0.05). Changes of mean %PA were 1AE12% and 7AE6% for BVS and DES (p¼0.07), respectively. There was a significant decrease of %PA at MLD (minimal lumen diameter) in BVS (-8AE12%) compared to metallic DES (4AE8%) (p¼0.01). Plaque tissue characterization (iMAP-IVUS, Boston Scientific) revealed that percentage changes of each plaque component were the same between the two device groups with a decrease of fibrotic and increase of lipid and necrotic components. Conclusions: At 1 year, plaque size trended towards reduction in Absorb but not in metallic DES implanted vessels. Plaque tissue characterization suggests that plaque stabilization has not occurred at 1 year; however, plaque stabilization is hypothesized to be related to tissue replacement of polymeric struts and as such expected during later stages of resorption. This hypothesis will be examined with repeat in vivo imaging follow-up and histological evaluation in these animals at 2, 3, and 4 years. 
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